Compare Adaptive Biotechnologies Corp (ADPT) vs US Bancorp (USB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs US Bancorp — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while US Bancorp trades at $61.03 (market cap $97.97B). The key difference: US Bancorp is far larger — about 29.4× Adaptive Biotechnologies Corp's market cap, and US Bancorp pays a 3.31% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | USB | |
|---|---|---|
Market Cap | $3.33B | $97.97B |
Sector | Health | Financials |
52-Week High | $22.37 | $62.89 |
52-Week Low | $10.24 | $43.94 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
U.S. Bancorp (USB) trades at $62.89, up 1.88% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company reported 2025 net income of $7.57 billion, with a net margin of 27.04%, and maintains a solid dividend history, including a recent $0.52 per share payout. Analyst consensus is mixed but leans positive, with a price target of $66.64.
USB's outlook is supported by robust profitability and strategic partnerships, but risks include interest rate sensitivity and competitive pressures. The stock offers value with a P/E of 13.17, though investors should monitor net cash flow trends and economic conditions affecting banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
